[HTML][HTML] Premature progesterone elevation in controlled ovarian stimulation: to make a long story short
E Adda-Herzog, M Poulain, D de Ziegler, JM Ayoubi… - Fertility and sterility, 2018 - Elsevier
Over the past decades many of us have contributed to the controversy surrounding the
origins and consequences of premature progesterone elevation during controlled ovarian …
origins and consequences of premature progesterone elevation during controlled ovarian …
[HTML][HTML] Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network …
C Rousset-Jablonski, F Selle, E Adda-Herzog… - European Journal of …, 2019 - Elsevier
Introduction Rare ovarian tumours include complex borderline ovarian tumours, sex-cord
tumours, germ cell tumours and rare epithelial tumours. Indications and modalities of fertility …
tumours, germ cell tumours and rare epithelial tumours. Indications and modalities of fertility …
[HTML][HTML] Steroid hormone pretreatments in assisted reproductive technology
J Nassar, T Tadros, E Adda-Herzog, JM Ayoubi… - Fertility and …, 2016 - Elsevier
Adequate availability and FSH sensitivity of ovarian antral follicles and coordination of their
growth during controlled ovarian hyperstimulation (COH) rank among factors that may …
growth during controlled ovarian hyperstimulation (COH) rank among factors that may …
Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: guidelines from the French national network …
C Rousset-Jablonski, F Selle, E Adda-Herzog… - Bulletin du …, 2018 - europepmc.org
INTRODUCTION: Rare ovarian tumors include complex borderline ovarian tumors, sex-cord
tumors, germ cell tumors, and rare epithelial tumors. Indications and modalities of fertility …
tumors, germ cell tumors, and rare epithelial tumors. Indications and modalities of fertility …
Segregation of mitochondrial DNA mutations in the human placenta: implication for prenatal diagnosis of mtDNA disorders
P Vachin, E Adda-Herzog, G Chalouhi, C Elie… - Journal of Medical …, 2018 - jmg.bmj.com
Background Mitochondrial DNA (mtDNA) disorders have a high clinical variability, mainly
explained by variation of the mutant load across tissues. The high recurrence risk of these …
explained by variation of the mutant load across tissues. The high recurrence risk of these …
Clinical predictive criteria associated with live birth following elective single embryo transfer
C Sifer, C Herbemont, E Adda-Herzog… - European Journal of …, 2014 - Elsevier
Objective We aimed to define clinical criteria from the patients related to the occurrence of
live birth in case of elective single embryo transfer (eSET). Study design We analyzed …
live birth in case of elective single embryo transfer (eSET). Study design We analyzed …
[CITATION][C] The Follicular Output RaTe (FORT): a marker of antral follicle responsiveness to FSH administration
É Adda-Herzog, R Fanchin - Médecine de la Reproduction, 2017 - jle.com
[3] Genro VK, Grynberg M., Scheffer JB, Roux I., Frydman R., Fanchin R. Serum anti-
müllerian hormone levels are negatively related to follicular output rate (FORT) in normo …
müllerian hormone levels are negatively related to follicular output rate (FORT) in normo …
Préservation de la fertilité, contraception et traitement hormonal de la ménopause chez les femmes traitées pour tumeurs malignes rares de l'ovaire: recommandations …
C Rousset-Jablonski, F Selle, E Adda-Herzog… - Bulletin du …, 2018 - Elsevier
Résumé Introduction Les tumeurs malignes rares de l'ovaire regroupent les tumeurs
borderline complexes, les tumeurs germinales, les tumeurs des cordons sexuels et les …
borderline complexes, les tumeurs germinales, les tumeurs des cordons sexuels et les …
Le follicular output rate : un marqueur de la sensibilité des follicules ŕ l'hormone folliculostimulante
É Adda-Herzog, R Fanchin - Médecine de la Reproduction, 2017 - jle.com
Le Follicular Output RaTe (FORT) est un marqueur que nous avons développé afin de
mesurer la réponse des follicules ŕ la stimulation par l'hormone folliculostimulante (FSH) …
mesurer la réponse des follicules ŕ la stimulation par l'hormone folliculostimulante (FSH) …
[CITATION][C] Menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological …
C Rousset-Jablonski… - …, 2018 - BMJ PUBLISHING GROUP BRITISH …